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ABSTRACT: A series of novel ruthenium(II) arene RAPTA type derivatives (arene =
cymene, hexamethylbenzene) containing curcumin-based ligands (curcH = curcumin,
bdcurcH = bisdemethoxycurcumin) and PTA (1,3,5-triaza-7-phosphaadamantane) have
been synthesized and fully characterized. The solid-state structures of [Ru(cym)(curc)-
(PTA)][SO3CF3], [Ru(hmb)(curc)(PTA)][SO3CF3], and [Ru(hmb)(bdcurc)(PTA)]-
[SO3CF3] have been determined by single-crystal X-ray diﬀraction. The antitumor activity
of the complexes has been evaluated in vitro against human ovarian carcinoma cells
(A2780 and A2780cisR), as well as against nontumorous human embryonic kidney
(HEK293) cells. The correlation of the cytotoxicity upon switching the curcumin-based
ligands, i.e. curcumin vs bisdemethoxycurcumin, is not straightforward. In contrast, the
PTA ligand greatly enhances the activity and selectivity of ruthenium compounds in comparison to previously reported
compounds.
■ INTRODUCTION
Platinum-based drugs are extensively used in the clinic to treat
many types of cancers.1 However, their application is limited by
severe side eﬀects and drug resistance, and consequently
complexes based on other metal ions have attracted attention.2
In this regard ruthenium-based compounds are among the most
promising, with two ruthenium(III) complexes undergoing
clinical evaluation.3 Organometallic ruthenium(II) arene
complexes also exhibit promising pharmacological properties.4
The relatively robust nature of ruthenium(II) arene complexes
allows their rational modiﬁcation such that an organic
compound of known therapeutic value may be tethered to
the motif. This type of modiﬁcation has been achieved via
covalent binding of the functional organic moiety to the arene5
or via one of the other ligands.6 Direct coordination of the
organic moiety, i.e. using it as a ligand, represents another
approach, and in this context ruthenium(II) arene complexes
have been derivatized with curcumin.7 Curcumin is a low-
molecular-weight polyphenol (Scheme 1a) and is the major
bioactive ingredient extracted from the rhizome of the plant
Curcuma longa (turmeric)8 that has a number of relevant
medicinal properties.9 Since curcumin possesses anti-inﬂamma-
tory, antioxidant, and antitumoral eﬀects, it has been extensively
studied as a chemopreventive agent in some cancer models and
used in the therapeutic selection in clinical oncology. However,
curcumin is insoluble and unstable in water.
As a continuation of previous works,7 water-soluble
ruthenium(II) arene compounds with curcumin-based ligands
were synthesized. Despite the fact that these compounds
displayed reasonable properties in vitro, we decided to replace
the chloride ligand with a 1,3,5-triaza-7-phosphaadamantane
ligand. Simple ruthenium(II) arene complexes with a PTA
ligand display antimetastatic activity in vivo,10 as well as an
intrinsic antiangiogenic activity11 and the ability to reduce the
growth of certain primary tumors.12
Herein we report novel derivatives containing both PTA and
curcuminoid ligands, their full solution and solid-state
characterization, and the study of their antiproliferative eﬀect
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against human ovarian carcinoma cells relative to nontumorous
human embryonic kidney cells.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of Ruthenium Com-
plexes. The desired ruthenium(II) arene complexes 1−6 were
prepared in high yield in a single step (Scheme 2), in which the
substitution of chloride ligand with PTA in the ruthenium
coordination environment is achieved by applying silver salts,
i.e. AgX, where X = SO3CF3, PF6.
Complexes 1−6 are air stable and soluble in alcohols,
acetone, acetonitrile, and DMSO and slightly soluble in
chlorinated solvents. The IR spectra of 2 and 5 display a
strong, sharp absorption at 825 and 826 cm−1 due to the PF6
counteranion,13 whereas the spectra of 1, 3, 4, and 6 contain a
characteristic absorption pattern in the region 1000−1200
cm−1, typical of a noncoordinated O3SCF3 anion.
14 The 1H
NMR spectra of 1−6 display all the expected signals due to the
coordinated arene rings, curc or bdcurc ligand, and PTA. The
resonances due to the PTA ligand are shifted to lower ﬁeld with
respect to those of uncoordinated PTA, conﬁrming its
coordination to the ruthenium center.15 The 31P NMR spectra
of 1, 2, 4, and 5, containing the p-cymene moiety, display a
singlet centered at ca. −26 ppm, whereas 3 and 6 with the
hexamethyl moiety show a resonance at −32 ppm, in the range
typical of related compounds and in accordance with the
existence of only one species in solution.16 The ESI mass
spectra of 1−6 show two main peak envelopes, that of highest
relative intensity corresponding to the intact [Ru(arene)(curc/
bdcurc)(PTA)]+ species and the other being due to the
[Ru(arene)(curc/bdcurc)]+ fragment formed upon PTA
dissociation.
The solid-state structures of 1, 3, and 6 were established by
X-ray crystallography (see the Experimental Section). Their
structures are shown in Figure 1, and principal bond parameters
are given in the caption. The bond lengths are essentially
typical values, although the O1−Ru1−O2 bond angles are
89.13(6), 87.78(7), and 87.9(2)° for 1, 3, and 6, respectively,
indicating that the six-membered metallacycle is less strained
than that observed in [Ru(η6-cym)(PTA)(C2O4)] (O1−Ru1−
O2 = 78.43(7)°),17 but is in keeping with the equivalent angles
in related complexes.18 In comparison, the two chloride ligands
coordinated to RAPTA-C are displaced at a bond angle of
89.16(4)°.19
The stability of 1 and 4 toward hydrolysis was studied under
pseudopharmacological conditions. The hydrolytic decomposi-
tion of the compounds was studied in 5 mM NaCl solution
Scheme 2. Synthesis of Complexes 1−6
Figure 1.Molecular structures of 1 (top), 3 (middle), and 6 (bottom).
Counterions and solvates have been omitted for clarity. Selected bond
lengths (Å) and angles (deg) for 1: Ru1−O2, 2.082(2); Ru1−O1,
2.089(2); Ru1−P1, 2.308(1); Ru1−η6, 1.713(1); O1−Ru1−O2,
89.13(6); P1−Ru1−O2, 83.43(5); P1−Ru1−O1, 88.89(5). Selected
bond lengths (Å) and angles (deg) for 3: Ru1−O2, 2.080(2); Ru1−
O1, 2.092(2); Ru1−P1, 2.324(1); Ru1−η6, 1.702(1); O1−Ru1−O2,
87.78(7); P1−Ru1−O2, 82.07(5); P1−Ru1−O1, 87.88(5). Selected
bond lengths (Å) and angles (deg) for 6: Ru1−O2, 2.086(6); Ru1−
O1, 2.091(5); Ru1−P1, 2.328(2); Ru1−η6, 1.707(6); O1−Ru1−O2,
87.9(2); P1−Ru1−O2, 83.2(2); P1−Ru1−O1, 86.9(2).
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(corresponding to the low intracellular NaCl concentration in
cells) and in 100 mM NaCl solution (approximating to the
higher NaCl levels in blood plasma). Solutions of the
complexes (c = 2.0 mM) in aqueous NaCl (c = 5 or 100
mM in D2O containing 10% [D6]DMSO) were prepared and
maintained at 37 °C for 7 days. Decomposition of the
complexes was monitored by 31P NMR spectroscopy. The
curcumin derivative 1 did not undergo hydrolyze in either
solution; i.e., the 31P NMR spectrum of 1 remained unchanged
in solution after 7 days. In contrast, the bisdemethoxycurcumin
derivative 4 immediately underwent partial substitution of the
chelating ligand in both 5 and 100 mM aqueous NaCl solution,
with two new singlets observed at −34.4 and −30.2 ppm,
together with a signal at −27.2 ppm corresponding to the
starting cationic species [Ru(cym)(bdcurc)(PTA)]+. After 1
day, the one species observed in the 100 mM aqueous NaCl
solution of 4 corresponded to [Ru(cym)(PTA)Cl2],
17 whereas
in the 5 mM aqueous NaCl solution only the starting complex,
[Ru(cym)(bdcurc)(PTA)]+, was observed.
The pKa values of the coordinated PTA ligands in 1 and 4
were determined by 31P NMR spectroscopy in D2O containing
10% DMSO, by measuring the chemical shift of the complexes
at diﬀerent pD values. The values obtained were plotted as
chemical shift vs pD (see Figure 2) and ﬁtted using the
Henderson−Hasselbach equation. The pKa value is obtained at
the midpoint of the curve, with 0.44 being subtracted to
account for the diﬀerence between the pH and pD.10
The pKa values of the free and coordinated ligands are
summarized in Table 1. The value for complex 1 is similar to
those of analogous compounds previously reported17,18 and
signiﬁcantly lower than those of RAPTA-C. In contrast, the pKa
determination of coordinated PTA in 4 was not possible, due to
the predominant formation of RAPTA-C on lowering the pD
with dilute HCl solution. In fact, the measured pKa corresponds
to that previously reported for RAPTA-C.10
The wavelengths and intensities of the bands in the
electronic absorption spectra of the free curcuminoid
proligands in DMSO and ethanol are given in Table 2. Each
free proligand exhibits a π−π* transition in the range 420−448
nm, where the maximum absorption is due to allowed π−π*
type excitations of their extended conjugate systems. The
assignment of this transition as π−π* was conﬁrmed by solvent
eﬀects. When the solvent was changed from ethanol to DMSO,
the transition shifted to a longer wavelength. In contrast, n−π*
transitions are characteristically shifted to shorter wavelengths
with increasing solvent polarity.20
The wavelengths and intensities of the bands in the
electronic absorption spectra of the ruthenium complexes
containing curc and bdcurc are summarized in Table 3.
All complexes display transitions in the range 450−500 nm
as shoulders, assignable to MLCT (metal−ligand charge
transfer) from the ﬁlled 4d orbitals of Ru(II) to the empty
π* ligand orbitals (4d6 Ru → π*)21 (Figure 3A,B). The
absorption spectra of curcH, bdcurcH, and all ruthenium
complexes in both DMSO and ethanol solutions are reported in
the Supporting Information (Figure 1S).
The emission spectra of proligands (0.045 mM) and
complexes 1−6 (0.045 mM) in DMSO (Figure 3C,D) were
obtained by irradiation with light of frequencies corresponding
to the maximum in their absorption spectra. The proligands are
Figure 2. 31P NMR chemical shift vs pD for 1.
Table 1. pKa Values for Complexes 1 and 4 in a 0.1 M NaCl
Solution
complex pKa
PTA 5.63 ± 0.05
RAPTA-C 3.13 ± 0.02
1 2.41 ± 0.02
Table 2. Wavelengths of Maximum Absorbance and
Extinction Coeﬃcients for Ligands in DMSO and Ethanol
DMSO ethanol
ligand λmax/nm ε/M
−1 cm−1 λmax/nm ε/M
−1 cm−1 assignt
curcH 268 11.155 264 11.167 n → π*
448 49.642 431 45.628 π → π*
bdcurcH 264 9.338 252 14.616 n → π*
426 53.732 420 53.626 π → π*
Table 3. Wavelengths of Maximum Absorbance and
Extinction Coeﬃcients for Ru(II) Arene Complexes
Containing Curcuminoid Ligands in DMSO and Ethanol
DMSO ethanol
compd λmax/nm
ε/M−1
cm−1 λmax/nm
ε/M−1
cm−1 assignt
1 252 12.367 235 11.936 n → π*
430 8.618 427 8.465 π → π*
481 (sh) 7.060 472 (sh) 6.457 Ru(4d6) → π*
2 252 12.283 234 11.851 n → π*
430 7.753 430 7.630 π → π*
483 (sh) 5.745 474 (sh) 6.322 Ru(4d6) → π*
3 251 13.227 235 12.811 n → π*
430 9.285 427 9.257 π → π*
480 (sh) 6.656 475 (sh) 7.698 Ru(4d6) → π*
4 253 11.487 234 11.603 n → π*
417 7.731 413 7.669 π → π*
480 (sh) 4.153 468 (sh) 5.113 Ru(4d6) → π*
5 253 11.467 234 11.318 n → π*
417 8.050 415 7.894 π → π*
479 (sh) 4.763 468 (sh) 5.379 Ru(4d6) → π*
6 252 11.893 235 11.893 n → π*
419 7.763 415 8.090 π → π*
478 (sh) 4.930 468 (sh) 5.654 Ru(4d6) → π*
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ﬂuorescent due to their extended aromatic systems. Complexes
1−3 re-emit at higher wavelengths and lower intensities with
respect to the free curcH. In contrast, in the case of the bdcurc
Ru(II) complexes, only 6 displays a lowering of intensity,
whereas 4 and 5 re-emit with intensities higher than that of the
free bdcurcH proligand. The lowest intensities are always
obtained with complexes containing the hmb moiety (3 and 6),
the six methyl substituents likely being responsible for the
deactivation of the emission process. The inversion in the
emissive behavior of the cymene complexes 4 and 5 (intensity
higher than that of free bdcurcH) with respect to 1 and 2
(lower intensity than free curcH) is due to the absence of
methoxy substituents in bdcurcH with respect to the curcH
proligand.
The ﬂuorescence data of curcH, bdcurcH, and all ruthenium
complexes in DMSO solutions are reported in the Supporting
Information (Table 2S).
Biological Studies. The cytotoxicity of 1−6 was evaluated
in vitro in comparison to that of cisplatin by determining the
IC50 concentration against human ovarian carcinoma A2780
cells and the A2780cisR variant with acquired resistance to
cisplatin as well as against nontumorous human embryonic
kidney (HEK293) cells. IC50 values for the compounds
determined after 72 h are presented in Table 4.
The new curcumin complexes display a highly promising
activity proﬁle. All complexes inhibit the growth of the tumor
cell lines at low micromolar concentrations and are more
potent than cisplatin, which is used in the clinic to treat ovarian
cancer,22 and curcumin itself (IC50 in A2780 and A2780cisR
cell lines 8 ± 1 and 11 ± 2 μM, respectively).23 Moreover, in all
cases the curcumin metal complexes show selectivity toward the
tumor cell lines (A2780 and A2780cisR) over the nontumorous
HEK293 cell line. In particular, 6 is approximately 70-fold more
active against the cancer cell line in comparison to the
noncancerous HEK cell line.
Complexes 1−6 are ca. 1−2 orders of magnitude more
cytotoxic than [Ru(cym)(curc)Cl] (23.4 ± 3.3 μM on A2780
cells), reported previously,7 and related compounds with β-
diketonate leaving groups.7c,18 RAPTA-C is essentially inactive
(IC50 > 250 μM) in the two ovarian cancer cell lines studied.
24
Moreover, switching the chloride ligand to the PTA ligand
results in complexes that overcome cisplatin resistance. Among
the six complexes there is little variation of cytotoxicity in the
ovarian cancer cell lines, and replacement of the cymene ligand
by the more lipophilic hexamethylbenzene ligand has only a
modest impact on the cytotoxic potency of the respective
complexes. In addition, switching the curcumin ligand to
bisdemethoxycurcumin does not give a straightforward trend.
The similar cytotoxicity proﬁles of the compounds are
remarkable given the extreme diﬀerences in hydrolysis of the
curcumin and bisdemethoxycurcumin ligands, the former being
inert and the latter readily dissociating. Thus, at this stage, it is
diﬃcult to postulate a mechanism of action, although the
cytotoxicity data suggest a common mechanism.
■ CONCLUSIONS
Curcumin has been extensively used as a food component and
has been shown to possess antioxidant, antiproliferative,
anticancer, and antiangiogenic properties, and many reports
have documented its eﬃcacy in the treatment of a number of
diseases.25 Previously reported ruthenium(II)−arene complexes
have been reported that show relevant cytotoxic eﬀects toward
cancer cells.7 Here, we have shown RAPTA-type complexes
containing curcumin-based ligands, as potential leaving groups
are endowed with not only superior solubility properties but
also superior cytotoxicites in comparison to other classes of
related compounds. On the cancer cell lines tested these new
compounds are ca. 100 fold more cytotoxic, with IC50 values
being typically ≤1 μM, while maintaining an excellent
selectivity index: i.e., they are considerably less cytotoxic to
nontumorous human embryonic kidney cells. The presence or
absence of peripheral methoxy groups in curcumin and the
diﬀerent arene rings do not strongly inﬂuence the biological
activity, despite leading to diﬀerences in hydrolysis rates,
whereas the PTA ligand appears to signiﬁcantly improve the
pharmacological properties of the curcumin-modiﬁed
ruthenium(II)−arene complexes. The superior cytotoxicity
and selectivity index in comparison to clinically used cisplatin
warrants the further development of these complexes.
■ EXPERIMENTAL SECTION
Materials and Methods. The dimers [(arene)RuCl2]2 (arene =
cym, hmb) were purchased from Aldrich. Curcumin and bisdemethox-
ycurcumin were purchased from TCI Europe and were used as
received. All other materials were obtained from commercial sources
and were used as received. IR spectra were recorded from 4000 to 600
cm−1 on a PerkinElmer Spectrum 100 FT-IR instrument. 1H and 13C
NMR spectra were recorded on a 400 Mercury Plus Varian instrument
operating at room temperature (400 MHz for 1H and 100 MHz for
13C) relative to TMS. Positive and negative ion electrospray ionization
Figure 3. UV−vis spectra of DMSO solutions of (A) curcH and
related Ru(II) arene complexes and (B) bdcurcH and related Ru(II)
arene complexes. Fluorescence spectra of DMSO solutions of (C)
curcH and related Ru(II) arene complexes and (D) bdcurcH and
related Ru(II) arene complexes.
Table 4. Cytotoxicity (IC50, μM) of 1−6 Following
Incubation for 72 h with Nontumorous Human Embryonic
Kidney HEK293 Cells and Ovarian Carcinoma A2780 and
A2780R (Cisplatin-Resistant) Cell Lines
compd HEK293 A2780 A2780cisR
1 4.5 ± 0.5 0.39 ± 0.16 0.36 ± 0.02
2 30 ± 1.0 1.15 ± 0.05 1.18 ± 0.02
3 9.1 ± 1.1 0.39 ± 0.01 0.40 ± 0.02
4 22 ± 4.0 0.81 ± 0.14 0.95 ± 0.21
5 2.0 ± 0.1 0.14 ± 0.05 0.51 ± 0.10
6 13 ± 2.0 0.20 ± 0.05 0.27 ± 0.03
cisplatin 7.3 ± 0.6 1.5 ± 0.2 25 ± 3.0
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mass spectra (ESI-MS) were obtained on a Series 1100 MSI detector
HP spectrometer using methanol as the mobile phase. Solutions (3
mg/mL) analysis were prepared using reagent-grade methanol. Masses
and intensities were compared to those calculated using IsoPro
Isotopic Abundance Simulator, version 2.1.28. Melting points are
uncorrected and were recorded on a STMP3 Stuart scientiﬁc
instrument and on a capillary apparatus. Samples for microanalysis
were dried in vacuo to constant weight (20 °C, ca. 0.1 Torr) and
analyzed on a Fisons Instruments 1108 CHNS-O elemental analyzer.
Electrical conductivity measurements (ΛM, reported as S cm2 mol−1)
of acetonitrile and dichloromethane solutions of the complexes were
recorded using a Crison CDTM 522 conductimeter at room
temperature. UV−vis spectra of the proligands and complexes were
performed with a Varian Cary1 spectrometer at 20 °C. The
ﬂuorescence of the proligands and complexes was analyzed using a
Hitachi F-4500 spectroﬂuorimeter at 20 °C.
Synthesis of Ruthenium Complexes. [Ru(cym)(curc)(PTA)]-
[SO3CF3] (1). Curcumin (curc, 368 mg, 1.00 mmol) was dissolved in
methanol (20 mL), and KOH (56 mg, 1.0 mmol) was added. The
mixture was stirred for 1 h at room temperature, and then
[Ru(cymene)Cl2]2 (306 mg, 0.50 mmol) was added. The resulting
mixture was stirred under reﬂux for 24 h, and then AgSO3CF3 (257
mg, 1 mmol) was added. The reaction mixture was stirred for 1 h and
ﬁltered to remove AgCl. PTA (PTA = 1,3,5-triaza-7-phosphaadaman-
tane; 157 mg, 1 mmol) was ﬁnally added to the ﬁltrate, which was
stirred for 24 h at room temperature. Then, the solvent was removed
and the crude product recrystallized from a 3/1 mixture of
dichloromethane and n-hexane (25 mL) by cooling to 4 °C until an
orange crystalline powder formed (491 mg, 0,54 mmol, yield 54%),
which was identiﬁed as 1. It is soluble in alcohols, acetone, acetonitrile,
and DMSO and slightly soluble in chlorinated solvents. Mp: 156−158
°C. Anal. Calcd for C38H45F3N3O9PRuS: C, 50.22; H, 4.99; N, 4.62.
Found: C, 50.02; H, 5.02. IR (cm−1): 2966 w, 1619 sh, 1590 m, 1498 s
ν(CC), 1270 m, 1156 s, 1027 s ν(SO3CF3). 1H NMR (DMSO, 293
K): δ 1.26 (d, 6H, CH3C6H4CH(CH3)2), 2.00 (s, 3H, CH3C6H4CH-
(CH3)2), 2.64 (m, 1H, CH3C6H4CH(CH3)2), 3.81 (s, 6H, OCH3 of
curc), 4.08 (dd, 6H, PTA), 4.41 (dd, 6H, PTA), 5.78 (s, 1H, C(1)H of
curc), 6.03 d, 6.09 d (4H, CH3C6H4CH(CH3)2), 6.68 (d, 2H, C(3,3′)
H of curc), 6.80 (d, 2H, C(10,10′)H of curc), 7.04 (d, 2H, C(9,9′)H
of curc), 7.22 (d, 2H, C(6,6′)H of curc), 7.32 (d, 2H, C(4,4′)H of
curc), 9.63 (s, 2H, OH of curc). 13C NMR (DMSO, 293 K): δ 17.0
(CH3C6H4CH(CH3)2), 22.4 (CH3C6H4CH(CH3)2), 30.7
(CH3C6H4CH(CH3)2), 51.2 (PCH2N, PTA), 56.4 (OCH3 of curc),
72.4 (NCH2N, PTA), 88.6, 90.4, 96.7 (CH3C6H4CH(CH3)2), 104.1
(C(1,1′) of curc), 105.1 (C(6,6′) of curc), 111.2 (C(9,9′) of curc),
116.4 (C(10,10′) of curc), 123.9 (C(5,5′) of curc), 127.2 (C(3,3′) of
curc), 140.4 (C(4,4′) of curc), 148.7 (C(7,7′) of curc), 149.8 (C(8,8′)
of curc), 180.3 (C(2,2′)O of curc). 31P NMR (DMSO, 293 K): δ
−25.8. ESI-MS (+) CH3OH (m/z [relative intensity, %]): 760 [100]
[Ru(cymene)(curc)(PTA)]+, 603 [20] [Ru(cymene)(curc)]+. Λm
(CH3OH, 298 K, 10
−3 mol/L): 88 S cm2 mol−1. Λm ((CH3)2SO,
298 K, 10−3 mol/L): 38 S cm2 mol−1.
[Ru(cym)(curc)(PTA)][PF6] (2). The synthesis was performed as for
1 using AgPF6. 2 is soluble in alcohols, acetone, acetonitrile, and
DMSO and slightly soluble in chlorinated solvents. Mp: 170−172 °C.
Anal. Calcd for C37H45F6N3O6P2Ru: C, 49,12; H, 5,01; N, 4,64.
Found: C, 48.95; H, 5.05; N, 4,54. IR (cm−1): 1605 sh, 1603 m, 1599
sh, 1497 s ν(CC), 825 s ν(PF6). 1H NMR (DMSO, 293 K): δ, 1.25
(d, 6H, CH3C6H4CH(CH3)2), 1.99 (s, 3H, CH3C6H4CH(CH3)2),
2.63 (m, 1H, CH3C6H4CH(CH3)2), 3.81 (s, 6H, OCH3 of curc), 4.08
(dd, 6H, PTA), 4.40 (dd, 6H, PTA), 5.78 (s, 1H, C(1)H of curc),
6.02d, 6.08d (4H, CH3C6H4CH(CH3)2), 6.67 (d, 2H, C(3,3′)H of
curc), 6.79 (d, 2H, C(10, 10′)H of curc), 7.03 (d, 2H, C(9,9′)H of
curc), 7.21 (d, 2H, C(6,6′)H of curc), 7.31 (d, 2H, C(4,4′)H of curc),
9.62 (s, 2H, OH of curc). 13C NMR (DMSO, 293 K): δ 17.0
(CH3C6H4CH(CH3)2), 22.4 (CH3C6H4CH(CH3)2), 30.7
(CH3C6H4CH(CH3)2), 51.2 (PCH2N, PTA), 56.3 (OCH3 of curc),
72.3 (N-CH2−N, PTA), 88.6, 90.3, 96.6 (CH3C6H4CH(CH3)2), 104.0
(C(1,1′) of curc), 105.0 (C(6,6′) of curc), 111.2 (C(9,9′) of curc),
116.4 (C(10,10′) of curc), 123.9 (C(5,5′) of curc), 127.2 (C(3,3′) of
curc), 140.4 (C(4,4′) of curc), 148.7 (C(7,7′) of curc), 149.8 (C(8,8′)
of curc), 180.3 (C(2,2′)O of curc). 31P NMR (DMSO, 293 K): δ
−26.0 (s, PTA), −143.1 (sept, PF6). ESI-MS (+) CH3OH (m/z
[relative intensity, %]): 760 [100][Ru(cymene)(curc)(PTA)]+, 603
[20] [Ru(cymene)(curc)]+. Λm (CH3OH, 298 K, 10−3 mol/L): 91 S
cm2 mol−1. Λm ((CH3)2SO, 298 K, 10−3 mol/L): 35 S cm2 mol−1.
[Ru(hmb)(curc)(PTA)][SO3CF3] (3). Compound 3 was prepared
following a procedure similar to that reported for 1 by using
[Ru(hmb)Cl2]2. 3 is soluble in alcohols, acetone, acetonitrile, and
DMSO and slightly soluble in chlorinated solvents. Mp: 201−203 °C.
Anal. Calcd for C40H49F3N3O9PRuS: C, 51.28; H, 5.27; N, 4.48.
Found: C, 50.98; H, 5.15; N, 4.36. IR (cm−1): 1619 w, 1590 m, 1498 s
ν(CC), 1273 m, 1157 s, 1028 s ν(SO3CF3). 1H NMR (DMSO, 293
K): δ 2.06 (s, 18H, CH3(hmb), 3.82 (s, 6H, PTA), 3.98 (s, 6H, PTA),
4.36 (s, 6H, OCH3 of curc), 5.78 (s, 1H, C(1)H of curc), 6.74−6.81
(br, 4H, C(3,3′)H and C(10,10′)H of curc), 7.08 (d, 2H, C(9,9′)H of
curc), 7.25 (d, 2H, C(6,6′)H of curc), 7.43 (d, 2H, C(4,4′)H of curc),
9.63 (s, 2H, OH of curc). 13C NMR (DMSO, 293 K): δ 15.5
(CH3(hmb), 48.8 (PCH2N, PTA), 56.1 (OCH3 of curc), 72.1
(NCH2N, PTA), 97.9 (C6(hmb), 104.2 (C(1,1′) of curc), 111.2
(C(6,6′) of curc), 116.1 (C(9,9′) of curc), 123.4 (C(10,10′) of curc),
125.0 (C(5,5′) of curc), 126.9 (C(3,3′) of curc), 139.5 (C(4,4′) of
curc), 148.4 (C(7,7′) of curc), 149.5 (C(8,8′) of curc), 179.3
(C(2,2′)O of curc). 31P NMR (DMSO, 293 K): δ −32.7. ESI-MS
(+) CH3OH (m/z [relative intensity, %]): 788 [100] [Ru(hmb)-
(curc)(PTA)]+, 631 [20] [Ru(hmb)(curc)]+. Λm (CH3OH, 298 K,
10−3 mol/L): 97 S cm2 mol−1. Λm ((CH3)2SO, 298 K, 10−3 mol/L):
42 S cm2 mol−1.
[Ru(cym)(bdcurc)(PTA)][SO3CF3] (4). Compound 4 was prepared
following a procedure similar to that reported for 1 by using bdcurc. 4
is soluble in alcohols, acetone, acetonitrile, and DMSO and slightly
soluble in chlorinated solvents. Mp: 184−186 °C. Anal. Calcd for
C36H41F3N3O7PRuS: C, 50.94; H, 4.87; N, 4.95. Found: C, 50.48; H,
4.73; N, 4.68. IR (cm−1): 3261 br, 1620 sh, 1601 m, 1584 sh, ν(C
C), 1269 m, 1155 s, 1025 s ν(SO3CF3).
1H NMR (DMSO, 293 K): δ
1.26 (d, 6H, CH3C6H4CH(CH3)2), 1.99 (s, 3H, CH3C6H4CH-
(CH3)2), 2.78 (m, 1H, CH3C6H4CH(CH3)2), 4.08 (sbr, 6H, PTA),
4.40 (sbr, 6H, PTA), 5.76 (s, 1H, C(1)H of bdcurc), 6.06 (dd, 4H,
CH3C6H4CH(CH3)2), 6.62, (d, 2H, C(4,4′)H of bdcurc), 6.79−6.83
(br, 4H, C(6,6′)H and C(10,10′)H of bdcurc), 7.33 (d, 2H, C(3,3′)H
of bdcurc), 7.46−7.55 (br, 4H, C(7,7′)H and C(9,9′)H of bdcurc),
10.01 (sbr, 2H, OH). 13C NMR (DMSO, 293 K): δ 16.6 (s,
CH3C6H4CH(CH3)2), 22.1 (s, CH3C6H4CH(CH3)2), 30.3 (s,
CH3C6H4CH(CH3)2), 50.9 (PCH2N, PTA), 72.1 (NCH2N, PTA),
88.3, 90.1, 96.2, 103.6 (s, CH3C6H4CH(CH3)2), 104.6 (s, C(1,1′) of
bdcurc), 116.3 (s, C(9,9′) and C(7,7′) of bdcurc), 123.4 (s, C(10,10′)
and C(6,6′) of bdcurc), 126.4 (s, C(5,5′) of bdcurc), 130.4 (s, C(3,3′)
of bdcurc), 139.9 (s, C(4,4′) of bdcurc), 159.9 (s, C(8,8′) of bdcurc),
180.0 (s, C(2,2′)O of bdcurc). 31P NMR (DMSO, 293 K): δ −26.0.
ESI-MS (+) CH3OH (m/z [relative intensity, %]): 700 [100]
[Ru(cymene)(bdcurc)(PTA)]+, 543 [20] [Ru(cymene)(bdcurc)]+.
Λm (CH3OH, 298 K, 10−3 mol/L): 91 S cm2 mol−1. Λm
((CH3)2SO, 298 K, 10
−3 mol/L): 41 S cm2 mol−1.
[Ru(cym)(bdcurc)(PTA)][PF6] (5). Compound 5 was prepared
following a procedure similar to that reported for 2 by using bdcurc.
5 is soluble in alcohols, acetone, acetonitrile, and DMSO and slightly
soluble in chlorinated solvents. Mp: 182−184 °C. Anal. Calcd for
C35H41F6N3O4P2Ru: C, 49.76; H, 4.89; N, 4.97. Found: C, 49.55; H,
4.69; N, 4.81. IR (cm−1): 1603 sh, 1601 m, 1598 sh, 1498 s ν(CC),
826 s ν(PF6).
1H NMR (DMSO, 298 K): δ 1.25 (d, 6H,
CH3C6H4CH(CH3)2), 1.99 (s, 3H, CH3C6H4CH(CH3)2), 2.77 (m,
1H, CH3C6H4CH(CH3)2), 4.07 (sbr, 6H, PTA), 4.40 (sbr, 6H, PTA),
5.76 (s, 1H, C(1)H of bdcurc), 6.06 (dd, 4H, CH3C6H4CH(CH3)2),
6.62, (d, 2H, C(4,4′)H of bdcurc), 6.79−6.83 (br, 4H, C(7,7′)H and
C(9,9′)H of bdcurc), 7.33 (d, 2H, C(3,3′)H of bdcurc), 7.48 (br, 4H,
C(6,6′)H and C(10,10′)H of bdcurc), 10.02 (sbr, 2H, OH). 13C NMR
(DMSO, 293 K): δ 16.6 (s, CH3C6H4CH(CH3)2), 22.1 (s,
CH3C6H4CH(CH3)2), 30.3 (s, CH3C6H4CH(CH3)2), 50.9 (PCH2N,
PTA), 72.1 (NCH2N, PTA), 88.3, 90.1, 96.2, 103.6 (s, CH3C6H4CH-
(CH3)2), 104.6 (s, C(1,1′) of bdcurc), 116.4 (s, C(9,9′) and C(7,7′) of
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bdcurc), 123.5 (s, C(10,10′) and C(6,6′) of bdcurc), 126.4 (s, C(5,5′)
of bdcurc), 130.6 (s, C(3,3′) of bdcurc), 139.8 (s, C(4,4′) of bdcurc),
159.9 (s, C(8,8′) of bdcurc), 180.0 (s, C(2,2′)O of bdcurc). 31P
NMR (DMSO, 298 K): δ −26.1 (s, PTA), −143.2 (sept, PF6). ESI-
MS (+) CH3OH (m/z [relative intensity, %]): 700 [100] [Ru-
(cymene)(bdcurc)(PTA)]+, 543 [10] [Ru(cymene)(bdcurc)]+. Λm
(CH3OH, 298 K, 10
−3 mol/L): 89 S cm2 mol−1. Λm ((CH3)2SO,
298 K, 10−3 mol/L): 44 S cm2 mol−1.
[Ru(hmb)(bdcurc)(PTA)][SO3CF3] (6). Compound 6 was prepared
following a procedure similar to that reported for 3 by using bdcurc. 6
is soluble in alcohols, acetone, acetonitrile, and DMSO and slightly
soluble in chlorinated solvents. Mp: 209−211 °C. Anal. Calcd for
C38H45F3N3O7PRuS: C, 52.05; H, 5.17; N, 4.79. Found: C, 51.92; H,
5.04; N, 4.62. IR (cm−1): 1604 sh, 1601 m, 1598 sh, 1497 s ν(CC),
1270 m, 1160 s, 1027 s ν(CF3SO3).
1H NMR (DMSO, 293 K): δ 2.07
(s, 18H, CH3hmb), 3.97 (s, 6H, PTA), 4.35 (s, 6H, PTA), 5.74 (s, 1H,
C(1)H of bdcurc), 6.70 (d, 2H, C(4,4′)H of bdcurc), 6.80 (br, 4H,
C(7,7′)H and C(9,9′)H of bdcurc), 7.45 (d, 2H, C(3,3′)H of bdcurc),
7.53 (br, 4H, C(6,6′)H and C(10,10′)H of bdcurc), 10.01 (sbr, 2H,
OH). 13C NMR (DMSO, 293 K): δ 15.4 (s, CH3hmb), 48.8 (s, PCH2N,
PTA), 72.1 (s, NCH2N, PTA), 98.0 (s, C6hmb), 104.6 (s, C(1,1′) of
bdcurc), 116.3 (s, C(9,9′) and C(7,7′) of bdcurc), 124.4 (s, C(10,10′)
and C(6,6′) of bdcurc), 126.5 (s, C(5,5′) of bdcurc), 130.6 (s, C(3,3′)
of bdcurc), 139.3 (s, C(4,4′) of bdcurc), 159.8 (s, C(8,8′) of bdcurc),
179.3 (s, C(2,2′)O of bdcurc). 31P NMR (DMSO, 298 K): δ −32.7.
ESI-MS (+) CH3OH (m/z [relative intensity, %]): 728 [80]
[Ru(hmb)(bdcurc)(PTA)]+, 571 [100] [Ru(hmb)(bdcurc)]+. Λm
(CH3OH, 298 K, 10
−3 mol/L): 95 S cm2 mol−1. Λm ((CH3)2SO,
298 K, 10−3 mol/L): 43 S cm2 mol−1.
X-ray Crystallography. The diﬀraction data of compounds 1 and
6 were measured at low temperature (100(2) K) using Mo Kα
radiation on a Bruker APEX II CCD diﬀractometer equipped with a κ
geometry goniometer. The data sets were reduced by EvalCCD26 and
then corrected for absorption.27 The data collection of compound 3
was carried out at low temperature (140(2) K) using Cu Kα radiation
on an Agilent Technologies SuperNova dual system in combination
with an Atlas CCD detector. The data reduction was carried out by
Crysalis PRO.28 The solutions and reﬁnements were performed with
SHELX.29 The crystal structures were reﬁned using full-matrix least
squares based on F2 with all non-hydrogen atoms anisotropically
deﬁned. Hydrogen atoms were placed in calculated positions by means
of the “riding” model.
Determination of pKa Values. The pH values of NMR samples
in D2O were measured at 298 K, directly in the NMR tube, using a 713
pH meter (Metrohm) equipped with an electrode calibrated with
buﬀer solutions at pH values of 4, 7, and 9. The pH values were
adjusted with dilute HCl and NaOH. The pH titration curves were
ﬁtted to the Henderson−Hasselbach equation using the program
Matlab (MathWorks Software), with the assumption that the observed
chemical shifts are weighted averages according to the populations of
the protonated and deprotonated species. The resonance frequencies
change smoothly with pH between the chemical shifts of the charged
form HA+, stable in acidic solution, and those of the neutral,
deprotonated form A, which is present at high pH. At any pH, the
observed chemical shift is a weighted average of the two extreme
values δ(HA+) and δ(A):
δ δ δ= +
+
+ +
+
(HA )[HA ] (A)[A]
[HA ] [A]av
The midpoint of the titration occurs when the concentrations of the
acid and its conjugate base are equal, [HA+] = [A]: that is, when the
pH equals the pKa of the compound. The pH at the midpoint of the
curve is corrected by subtracting 0.44 to the pD values, since the
measurements were made in D2O.
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Cell Culture and Inhibition of Cell Growth. The human A2780
and A2780cisR ovarian carcinoma and HEK (human embryonic
kidney) cells were obtained from the European Collection of Cell
Cultures (Salisbury, U.K.). A2780 and A2780cisR cells were grown
routinely in RPMI-1640 medium, while HEK cells were grown in
DMEM medium, with 10% fetal bovine serum (FBS) and 1%
antibiotics at 37 °C and 5% CO2. Cytotoxicity was determined using
the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide). Cells were seeded in 96-well plates as
monolayers with 100 μL of cell suspension (approximately 5000
cells) per well and preincubated for 24 h in medium supplemented
with 10% FBS. Compounds were prepared as DMSO solutions and
then dissolved in the culture medium and serially diluted to the
appropriate concentration, to give a ﬁnal DMSO concentration of
0.5%. A 100 μL portion of the solution was added to each well, and the
plates were incubated for another 72 h. Subsequently, MTT (5 mg/
mL solution) was added to the cells and the plates were incubated for
a further 2 h. The culture medium was aspirated, and the purple
formazan crystals formed by the mitochondrial dehydrogenase activity
of vital cells were dissolved in DMSO. The optical density, directly
proportional to the number of surviving cells, was quantiﬁed at 590 nm
using a multiwell plate reader, and the fraction of surviving cells was
calculated from the absorbance of untreated control cells. Evaluation is
based on means from at least two independent experiments, each
comprising triplicates per concentration level.
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Llorens, R.; Moreno, V. J. Inorg. Biochem. 2012, 117, 171−188.
(8) (a) Aggarwal, B. B.; Sundaram, C.; Malani, N.; Ichikawa, H.
Curcumin: The Indian solid gold; Springer: New York, 2007. (b) Yang,
F.; Lim, P. L. G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.;
Ambegaokar, S. S.; Chen, P.; Kayed, R.; Glabe, C. G.; Frautschy S. A.
Cole, G. M. J. Biol. Chem. 2004, 280, 5892−5901. (c) Aggarwal, B. B.;
Kumar, A.; Bharti, A. C. Anticancer Res. 2003, 23, 363−398.
(9) For selected examples see: (a) Renfrew, A. K.; Bryce, N. S.;
Hambley, T. W. Chem. Sci. 2013, 4, 3731−3739. (b) Banerjee, S.;
Prasad, P.; Hussain, A.; Khan, I.; Kondaiah, P.; Chakravarty, A. R.
Chem. Commun. 2012, 48, 7702−7704. (c) Sagnou, M.; Benaki, D.;
Triantis, C.; Tsotakos, T.; Psycharis, V.; Raptopoulou, C. P.; Pirmettis,
I.; Papadopoulos, M.; Pelecanou, M. Inorg. Chem. 2011, 50, 1295−
1303. (d) Song, X. Y.-M.; Xu, J.-P.; Ding, L.; Hou, Q.; Liu, J.-W.; Zhu,
Z.-L. J. Inorg. Biochem. 2009, 103, 396−400. (e) Ferrari, E.; Lazzari, S.;
Marverti, G.; Pignedoli, F.; Spagnolo, F.; Saladini, M. Bioorg. Med.
Chem. 2009, 17, 3043−3052. (f) Valentini, A.; Conforti, F.; Crispini,
A.; De Martino, A.; Condello, R.; Stellitano, C.; Rotilio, G.; Ghedini,
M.; Federici, G.; Bernardini, S.; Pucci, D. J. Med. Chem. 2009, 52,
484−491. (g) Mohammadi, K.; Thompson, K. H.; Patrick, B. O.;
Storr, T.; Martins, C.; Polishchuk, E.; Yuen, V. G.; McNeill, J. H.;
Orvig, C. J. Inorg. Biochem. 2005, 99, 2217−2225.
(10) Scolaro, C.; Bergamo, A.; Brescacin, L.; Delfino, R.; Cocchietto,
M.; Laurenczy, G.; Geldbach, T. J.; Sava, G.; Dyson, P. J. J. Med. Chem.
2005, 48, 4161−4171.
(11) Nowak-Sliwinska, P.; van Beijnum, J. R.; Casini, A.; Nazarov, A.
A.; Wagnieres, G.; van den Bergh, H.; Dyson, P. J.; Griffioen, A. W. J.
Med. Chem. 2011, 54, 3895−3902.
(12) Chatterjee, S.; Kundu, S.; Bhattacharyya, A.; Hartinger, C. G.;
Dyson, P. J. J. Biol. Inorg. Chem. 2008, 13, 1149−1155.
(13) (a) Kruck, T. Angew. Chem., Int. Ed. 1967, 6, 53−67.
(b) Collong, W.; Kruck, T. Chem. Ber. 1990, 123, 1655−1656.
(c) Fuss, W.; Ruhe, M. Z. Naturforsch., B 1992, 47B, 1.
(14) Nakamoto, K. Infrared and Raman Spectra of Inorganic and
Coordination Compounds, 5th ed.; Wiley: New York, 1997; Part B, Vol.
I-3, p 79.
(15) Wanke, R.; Smolenski, P.; Guedes da Silva, M. F. C.; Martins, L.
M. D. R. S.; Pombeiro, A. J. L. Inorg. Chem. 2008, 47, 10158−10168.
(16) Kilpin, K. J.; Clavel, C. M.; Edafe, F.; Dyson, P. J.
Organometallics 2012, 31, 7031−7039.
(17) Ang, W. H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-
Jeannerat, L.; Dyson, P. J. Inorg. Chem. 2006, 45, 9006−9013.
(18) Vock, C. A.; Renfrew, A. K.; Scopelliti, R.; Juillerat-Jeanneret, L.;
Dyson, P. J. Eur. J. Inorg. Chem. 2008, 1661−1671.
(19) Allardyce, C. S.; Dyson, P. J.; Ellis, D. J.; Heath, S. L. Chem.
Commun. 2001, 1396−1397.
(20) Lambert, J. B.; Shurvell, H. F., Lightner, D. A., Cooks, R. G.
Organic Structural Spectroscopy; Prentice Hall: New York, 1998.
(21) Dougan, S. J.; Melchart, M.; Habtemariam, A.; Parsons, S.;
Sadler, P. J. Inorg. Chem. 2006, 45, 10882−10894.
(22) Wheate, N. J.; Walker, S.; Craiga, G. E.; Ouna, R. Dalton Trans.
2010, 39, 8113−8127.
(23) Ferrari, E.; Pignedoli, F.; Imbriano, C.; Marverti, G.; Basile, V.;
Venturi, E.; Saladini, M. J. Med. Chem. 2011, 54, 8066−8077.
(24) Adhireksan, Z.; Davey, G. E.; Campomanes, P. R.; Groessl, M.;
Clavel, C.; Yu, H.; Nazarov, A. A.; Yeo, C. H. F.; Ang, W. H.; Dröge,
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